Marshall Anderson, PhD, is Professor of Medicine at the Medical College of Wisconsin in the Division of Hematology and Oncology. Dr. Anderson's research is focused on the genetic, etiology, and prevention of lung cancer. Dr. Anderson and his team have formed a consortium to study familial lung cancer. Genetic Epidemiology of Lung Cancer Consortium (GELCC) includes scientists from Mayo Clinic, MD Anderson, University of Cincinnati, MCW, LSU College of Medicine in New Orleans, Kormann Cancer Center, and University of Toledo MSC.
A second research effort is analysis of anti-apoptotic proteins that modulates apoptosis pathways. We recently identified a novel anti-apoptotic protein which modulates mitochondrial apoptosis pathways. We designated this ubiquitously expressed and evolutionary conserved anti-apoptotic protein as conserved-anti-apoptotic protein (CAAP). One of the apoptotic pathways that the CAAP modulates is a Caspase-10 dependent pathway. Our data suggests that the CAAP protein could be a target for some chemotherapeutic agents.
The third project is based on our identifying several small chemicals that inhibit the activation of NF-kB induced by chemotherapeutic agents. This activation of NF-kB induces anti-apoptotic proteins which reduces the efficacy of cancer drugs. We are now testing the compounds in cell lines to compare the induction of apoptosis with chemotherapeutic agents alone and in combination with curcumin or our test compounds.
Our goal is to test at least 2 of these compounds in the nude mouse model.